Fewer new drugs launched in the US in 2022 than in recent years, but the year's new launches included some stellar commercial performers, such as Pfizer Inc.'s Paxlovid (nirmarelvir/ritonavir), Roche Holding AG's Vabysmo (faricimab) and Eli Lilly and Company's Mounjaro (tirzepatide). The year's class also included some promising scientific advances including three new gene therapies and a new drug in the notoriously challenging area of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, Inc.'s Relyvrio (sodium phenylbutyrate/taurusodiol).
Around 40 new drugs launched in the US in 2022, the lowest number since 2016. ([A#3SC098446]) Not all of the drugs approved by the US Food and Drug Administration in 2022 necessarily launched during the year. For example, Revance Therapeutics, Inc. has delayed the launch of Daxxify (daxibotulinumtoxinA), a new Botox competitor for an exclusive preview in December followed by a full commercial launch in the second quarter of 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
